ORKA — Oruka Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 907654 ·
Last close
$96.51
Market Cap
$5.82B
52W High
$99.00
52W Low
$53.62
ADV30
1,543,070
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -36,434,000 | -31,820,000 | 504,480,000 | 49,520,000 | 20,691,000 |
| Dec 2025 | 0 | — | -34,431,000 | -29,583,000 | 488,617,000 | 46,935,000 | 19,618,000 |
| Sep 2025 | 0 | — | -34,105,000 | -30,277,000 | 509,251,000 | 91,253,000 | 22,460,000 |
| Jun 2025 | 0 | — | -28,429,000 | -24,574,000 | 357,418,000 | 65,396,000 | 13,776,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-90,919,000
Investing CF
$-154,048,000
Financing CF
$210,915,000
CapEx
$-269,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.89
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-220,977,000
Inventory
—
Receivables
$0
ST Investments
$339,309,000
EBIT TTM
$-120,868,000
Pretax Income TTM
$-116,254,000
Interest Exp TTM
$0
Analysts
12
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -122,051,000 | -105,433,000 | 488,617,000 | 19,618,000 | — | -88,210,000 |
| Dec 2024 | — | — | — | 396,019,000 | 16,729,000 | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.49
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $5.84B | $106.92 | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.85B | $18.32 | — |
| LGND | LIGAND PHARMACEUTICALS INC | $5.76B | $287.54 | — |
| PTCT | PTC THERAPEUTICS, INC. | $5.68B | $68.01 | — |
| XENE | Xenon Pharmaceuticals Inc. | $6.06B | $62.67 | — |
News headlines (Yahoo Finance, 1h cache)
HMI Capital Pares Its Stake in AI Company nCino
2026-07-10 23:26 · Yahoo
H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News
2026-07-01 21:23 · Yahoo
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
2026-06-27 19:48 · Yahoo
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?
2026-06-24 21:44 · Yahoo
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?
2026-06-12 16:00 · Yahoo
Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade
2026-06-10 13:55 · Yahoo
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million
2026-05-31 14:41 · Yahoo
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-28 12:00 · Yahoo
Oruka Therapeutics (ORKA) Valuation Check After Psoriasis Trial Progress Partnerships And Fresh Funding
2026-05-15 15:18 · Yahoo
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
2026-05-13 21:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.